- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Utilizing Health Economic Outcomes in Clinical Practice
Panelists discuss how patient financial burden varies significantly by insurance type and often leads to treatment interruptions, while prior authorization barriers create administrative challenges that could be improved through better collaboration between medical and payer communities.
EP: 1.Pathophysiology of Pulmonary Arterial Hypertension
EP: 2.Differential Diagnosis of Pulmonary Arterial Hypertension
EP: 3.Importance of Early Detection and Monitoring for Disease Progression
EP: 4.Risk Stratification and the Importance of Patient-Centered Care
EP: 5.Strengths and Limitations of Current Therapeutic Options
EP: 6.Overview of Different Therapies for Patients with Pulmonary Arterial Hypertension
EP: 7.Sotatercept for Patients with Pulmonary Arterial Hypertension
EP: 8. The Role of the Prostacyclin Pathway
EP: 9.Important Clinical Considerations for Pulmonary Arterial Hypertension
EP: 10.Economic Impact of Pulmonary Arterial Hypertension
EP: 11.Barriers to Care for Patients with Pulmonary Arterial Hypertension
EP: 12.Utilizing Health Economic Outcomes in Clinical Practice
EP: 13.Outlining the Need for Equitable Access to Care
EP: 14.Final Panelist Thoughts on the Management of Pulmonary Arterial Hypertension
Future Therapeutic Directions and Disease Remission
The future vision for PAH treatment centers on achieving disease remission, either partial or complete, fundamentally changing the disease trajectory from fatal progression to manageable chronic condition. This paradigm shift requires therapies that work through reverse remodeling mechanisms rather than solely providing symptomatic improvement. Sotatercept represents the first approved therapy with potential reverse remodeling properties, with several other compounds in development targeting similar mechanisms.
Investigational therapies showing promise include seralutinib, bardoxolone, and other compounds that may contribute to the reverse remodeling approach. The concept involves bringing PAH to a stage where patients can achieve normal life expectancy and quality of life despite having the disease. This vision suggests that within ten years, fewer patients may require parenteral prostacyclin therapy or lung transplantation if effective reverse remodeling therapies become widely available.
Future treatment approaches will likely incorporate personalized medicine principles, allowing selection of optimal therapy based on individual patient biology rather than current trial-and-error approaches. The development of multiple reverse remodeling agents combined with better patient phenotyping may enable achievement of disease remission in the majority of PAH patients, fundamentally altering the prognosis and management of this previously fatal condition.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
